Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD tropifexor, licogliflozin - FXR agonist and SGLT 1/2 inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04065841 ELIVATE (CLJN452D12201C) Non-alcoholic steatohepatitis (NASH) Phase 2 380 Proportion of patients with resolution of NASH and no worsening of fibrosis OR improvement in fibrosis by at least one stage without worsening of NASH at Week 48 compared with baseline Arm A: combination therapytropifexor + licogliflozin Arm B: tropifexor monotherapytropifexor + licogliflozin placebo Arm C: licogliflozin monotherapylicogliflozin + tropifexor placebo Arm D: licogliflozin placebo + tropifexor placebo Adult patients with biopsy based non-alcoholic steatohepatitis (NASH) and liver fibrosis Target Patients Read-out Milesstone(s) Publication 2023 2023 85 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation